Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study.
about
Pharmacological treatments for fatigue associated with palliative carePharmacological treatments for fatigue associated with palliative careInterventions for fatigue management after traumatic brain injuryPharmacological treatments for fatigue associated with palliative care: executive summary of a Cochrane Collaboration systematic reviewFatigue Management in Multiple SclerosisMultiple sclerosisCytokine effects on the basal ganglia and dopamine function: the subcortical source of inflammatory malaiseThe Berlin Treatment Algorithm: recommendations for tailored innovative therapeutic strategies for multiple sclerosis-related fatigueApproved and investigational uses of modafinil : an evidence-based reviewPsychopathology in multiple sclerosis: diagnosis, prevalence and treatmentEfficacy of modafinil on fatigue and excessive daytime sleepiness associated with neurological disorders: a systematic review and meta-analysisDrugs for sleep disorders: mechanisms and therapeutic prospectsThe dopamine imbalance hypothesis of fatigue in multiple sclerosis and other neurological disorders.Meta-analysis of three different types of fatigue management interventions for people with multiple sclerosis: exercise, education, and medicationBody temperature is elevated and linked to fatigue in relapsing-remitting multiple sclerosis, even without heat exposure.Fatigue in cancer: a review of literatureFatigue in multiple sclerosis: mechanisms, evaluation, and treatmentRelationship between depression, fatigue, subjective cognitive impairment, and objective neuropsychological functioning in patients with multiple sclerosis.Effects of multidisciplinary rehabilitation on chronic fatigue in multiple sclerosis: a randomized controlled trialNew approaches in the management of multiple sclerosis.An open study of modafinil for the treatment of daytime somnolence and fatigue in primary biliary cirrhosis.Modafinil in the treatment of debilitating fatigue in primary biliary cirrhosis: a clinical experience.Pharmacological treatment of chronic fatigue syndrome: focusing on the role of antidepressants.Symptomatic therapy in multiple sclerosis: a review for a multimodal approach in clinical practice.Treatment of fatigue in multiple sclerosis patients: a neurocognitive approach.Association of multiple sclerosis with restless legs syndrome and other sleep disorders in women.Treatment of symptoms in multiple sclerosis.Tyrosine metabolism during interferon-alpha administration: association with fatigue and CSF dopamine concentrationsOrigin of fatigue in multiple sclerosis: review of the literature.Fatigue in neuroimmunological diseases.Effects of glatiramer acetate on fatigue and days of absence from work in first-time treated relapsing-remitting multiple sclerosis.Armodafinil for sarcoidosis-associated fatigue: a double-blind, placebo-controlled, crossover trial.Fatigue in palliative care patients -- an EAPC approach.Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications.Treatment of fatigue in multiple sclerosis: a systematic review of the literature.The treatment of fatigue.Fatigue and sleep-disordered breathing in multiple sclerosis: a clinically relevant association?Disease-modifying agents for multiple sclerosis: recent advances and future prospects.Effect of eszopiclone on sleep disturbances and daytime fatigue in multiple sclerosis patients.Pilot study of Panax quinquefolius (American ginseng) to improve cancer-related fatigue: a randomized, double-blind, dose-finding evaluation: NCCTG trial N03CA.
P2860
Q24187756-4B6F3B25-8312-44CC-931C-0BB523048BEDQ24236457-5F160FF7-EF5E-4873-8F36-17EFE29E7207Q24245645-43A9123A-15F6-4F62-9BBB-B53E7DC1BF94Q26749413-0F35EABF-9370-4F63-B59B-AE60AC5BF676Q26752946-6F860788-090D-4E2B-86C5-15D88F9C3696Q26995437-2E173549-F154-4262-9F57-A720F6F23CE8Q27001628-58497472-0DB6-4060-B1CC-E7C15B7D1B78Q28073849-9EAA4320-BC95-4A07-A1C9-DE7BBBF5454DQ28291968-9331CFCD-E005-4338-AD69-20B3CAC61F92Q28301691-4F8BB862-4861-41ED-AF9A-6465C0691A7CQ28535752-04707EAF-12E8-4F53-8252-57098207DE2AQ30498393-0431B689-00A3-459C-A21E-63F9C7A97C5CQ30917626-9366F6CF-7709-4387-AEAC-44790F88A27AQ33735739-7987C52C-5746-4EC7-B9E8-232FE0A4841EQ33807332-DD0B944E-E6A9-493F-9ED7-F886E2C64BA3Q33915622-20357A65-2BF9-4FB1-823B-344EB9D53FEFQ34021881-BD280CF5-95F7-451E-A413-9681D5C3C46BQ34102803-20ED7B42-42A7-4359-AFEB-1805FFF71E57Q34214944-16CF67F1-1612-4616-8569-DBDF3D55A103Q34389528-25F9E53B-CE40-4467-8888-CE6954E31E13Q34608494-2E3C9035-9FA2-42B3-9EF7-17C2EDC64EDCQ34904107-03243CE2-9881-4749-AD91-66D699E76557Q34985957-91CBC3BB-AA6F-4EA0-AC80-BE25E04D3195Q35018491-83B1FDCC-ED71-4BAC-8ACA-8AEEF063E062Q35390868-A4FB197A-79B6-4C19-A786-E128968E534AQ35937981-F5D4C240-E2F1-4628-BB6C-E8E8292467E7Q36474348-4D144E20-8F40-45C8-BAD1-BCB8478484D0Q36628420-724C9E8A-D247-4DDB-8E49-4BAC33748D63Q36780439-91470617-7E0C-4D96-869D-02E774726748Q36822048-7F702D21-5BB3-40A3-A9C6-DDE35F5B4922Q36889694-7372C552-8191-4F0B-A8B6-4548C92A05EEQ36917907-68221EF6-3145-434E-B92B-3E974F29B38AQ37063833-2C0B0A24-278E-42E6-84CD-26ED1D1BD423Q37089253-662424E1-EE73-4269-9CFB-52AE2DE215C1Q37100322-89FED3A2-A4A6-4F3F-996D-AE11F3C19807Q37238934-236CEA50-6A3E-4E02-8A4F-3B13BEADAC32Q37285887-AE2B2007-55B5-49E8-96A4-075F7DF3BF1BQ37328280-12C89942-E9F2-47D2-80D5-3BE30A4A8CE7Q37442056-62A8A85D-73E7-49C8-A5E3-E2B917947B1FQ37548284-BB79B0B5-A6CB-4914-87AB-ACD9AEBA67DF
P2860
Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study.
@en
type
label
Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study.
@en
prefLabel
Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study.
@en
P2093
P1433
P1476
Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study.
@en
P2093
B Stankoff
C Confavreux
C Lubetzki
French Modafinil Study Group
J Pelletier
M Debouverie
P304
P356
10.1212/01.WNL.0000158272.27070.6A
P407
P577
2005-04-01T00:00:00Z